Lv61
2520 积分 2022-06-14 加入
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer
1个月前
已完结
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial
1个月前
已完结
Computational model predicts patient outcomes in Luminal B breast cancer treated with endocrine therapy and CDK4/6 inhibition
1个月前
已完结
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer
1个月前
已完结
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial
3个月前
已完结
Global Stage Distribution of Breast Cancer at Diagnosis
4个月前
已完结
How chemokines organize the tumour microenvironment
4个月前
已完结
Harnessing cytokines and chemokines for cancer therapy
4个月前
已完结
Resolving genetic heterogeneity in cancer
4个月前
已完结
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data
4个月前
已完结
皖公网安备34019202002308
